HomeBUSINESS
BUSINESS

Olmesartan Lawsuit Settlement in US Now Valid: Daiichi Sankyo
(Jun.7.2018)

Daiichi Sankyo said on June 6 that a previously announced settlement deal in US product liability litigation over its hypertension treatment olmesartan has become valid now that more than 97% of eligible claimants have opted in ...
(LOG IN FOR FULL STORY)